Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

VRCTC-310 — A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity

Summary

Two purified animal venom toxins, crotoxin and cardiotoxin, have been combined to produce a unique natural product (VRCTC-310) currently under investigation as an antitumor agent by the National Cancer Institute.In vitro, it has demonstrated cytotoxic disease specificity and a unique mechanism of action when submitted to COMPARE analysis.In vivo, tolerance was developed to the neurotoxic properties of crotoxin which allowed comparison of several schedules of fixed and escalating daily i.m. doses to mice bearing s.c. Lewis Lung carcinoma. An 83% inhibition of tumor growth was achieved using an escalating dose schedule starting at 1.8 mg/kg and reaching 6.3 mg/kg/day on day 20. Although some irritation around the sites of i.m. injection was noted, animal weight loss was negligible and there were no other signs of adverse toxicity. This natural product represents a new, membrane interactive anticancer agent which produces a unique spectrum of cytotoxicityin vitro and which has demonstrated interestingin vivo antitumor efficacy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Tu AT, Giltner JB: Cytotoxic effects of snake venoms on KB and Yoshida sarcoma cells. Res Commun Chem Pathol Pharmacol 9:783, 1974

  2. 2.

    Chaim-Matyas A, Ovadia M: Cytotoxic activity of various snake venoms on melanoma B16F10 and chondrosarcoma. Life Sci 40:1601–1607, 1987

  3. 3.

    Braganca BM, Patel NT, Badrinath PG: Isolation of a cobra venom factor selectively cytotoxic to Yoshida sarcoma cells. Biochim Biophys Acta, 136:508, 1967.

  4. 4.

    Kaneda N, Hamaguchi M, Kojima K, Kaneshima H, Hayashi K: Action of cobra venom cardiotoxin on chick embryonal fibroblasts transformed with a temperature-sensitive mutant of Rous sarcoma virus. FEBS Lett 192:313–316, 1985

  5. 5.

    Chwetzoff S, Tsunawawa S, Sakiyama F, Menez A: Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. J Biol Chem 264:13289–13297, 1989

  6. 6.

    Corin RE, Viskatis LJ, Vidal JC, Etcheverry MA: Cytotoxicity of the crotoxin complex on murine erythroleukemia cells. Inv New Drugs. (In press)

  7. 7.

    Okamoto M, Viskatis LJ, de la Roza G, Vidal JC: Induction of tolerance to crotoxin in mice. J Pharmacol Exp Therap 265:41–46, 1993

  8. 8.

    Hendon RA, Fraenkel-Conrat H: Biological roles of the two components of crotoxin. Proc Natl Acad Sci USA 68: 1560–1563, 1971

  9. 9.

    Harvey A: Cardiotoxins from cobra venoms: Possible mechanisms of action. J Toxicol Tox Rev 4:41–69, 1985

  10. 10.

    Habermann E, Breithaupt H: Mini-Review: The crotoxin complex — An example of biochemical and pharmacological protein complementation. Toxicon 16:19–30, 1978

  11. 11.

    Monks A, Scudeiro D, Shehan P, Schoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Institute 83:757–766, 1991

  12. 12.

    Seki C, Vidal JC, Barrio A: Purification of gyroxin from the South American rattlesnake (Crotalus durissus terrificus) venom. Toxicon 18:235–242, 1980

  13. 13.

    Aird SD, Kaiser II: Comparative studies of three rattlesnake toxins. Toxicon 23:361–374, 1985

  14. 14.

    Yang CC, King K, Sun TP: Chemical modification of lysine and histidine residues in phospholipase A2 from the venom ofNaja Naja Atra (Taiwan Cobra). Toxicon 19:645–659, 1981

  15. 15.

    Faure G, Bon C: Crotoxin, a phospholipase A2 neurotoxin from the South American rattlesnakeCrotalus Durissus Terrificus: Purification of several isoforms and comparison of their molecular structure and of their biological activities. Biochemistry 27:732–738, 1987.

  16. 16.

    Hodges SJ, Agbaji AS, Harvey AL, Hider RC: Cobra cardiotoxins — purification, effects on skeletal muscle and structure/activity relationships. Eur J Biochem 165:373–383, 1987

  17. 17.

    Meier J, Theakston RDG: Approximate LD50 determinations of snake venoms using eight to ten experimental animals. Toxicon 24:395–401, 1986

  18. 18.

    Gad S, Weil CS, Statistics, Experimental Design for the Toxicologist, Caldwell, NJ, Telford Press, 1988, pp. 72–74

  19. 19.

    Cochran WG, Cox GM, Experimental Designs, New York, John Wiley & Sons Inc., 1975, pp. 100–102

  20. 20.

    Lewin NE, DellAquila ML, Pettit GR, Blumberg PM, Warren BS: Binding of [3H]bryostatin 4 to protein kinase C. Biochem Pharmacol 43:2007–2014, 1992

  21. 21.

    Bai R, Friedman SJ, Pettit GR, Hamel E: Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 43:2637–2645, 1992

  22. 22.

    Hendon RA, Tu AT: The role of crotoxin subunits in tropical rattlesnake neurotoxic action. Biochim Biophys Acta 578:243–252, 1979

  23. 23.

    Rosenberg P: Phospholipases. In: Shier WT and Mebs D (eds), Handbook of Toxinology, New York, Marcel Dekker Inc., 1990, p. 87

  24. 24.

    Kini RM, Evans HJ: A model to explain the pharmacological effects of snake venom phospholipases A2. Toxicon 27: 613–635, 1989

  25. 25.

    Bougis P, Rochat H, Pieroni G, Verger R: Penetration of phospholipid monolayer by cardiotoxin. Biochemistry 20: 4915–4920, 1981

  26. 26.

    Condrea E: Membrane active polypeptides from snake venoms: Cardiotoxins and haemocytotoxins. Experientia 30:121–216, 1974

  27. 27.

    Louw AI, Visser L: The synergism of cardiotoxin and phospholipase A2 in hemolysis. Biochim Biophys Acta 512:163–171, 1978

  28. 28.

    Cheng YH, Hu CT, Yang JT: Membrane disintegration and hemolysis of human erythrocytes by snake venom cardiotoxin (a membrane-disruptive polypeptide). Biochem Int 8:329–338, 1984

  29. 29.

    Gopalakrishnakone P, Dempster DW, Hagwood BJ, Elder HY: Cellular and mitochondrial changes induced in the structure of murine skeletal muscle by crotoxin, a neurotoxic phospholipase A2 complex. Toxicon 22:85–98, 1984

  30. 30.

    Kouyoumdjian JA, Harris JB, Johnson MA: Muscle necrosis caused by the subunits of crotoxin. Toxicon 24:575–583, 1986

  31. 31.

    Lee CY, Chang CC, Chiu TH, Chiu PJS, Tseng TC, Lee SY: Pharmacological properties of cardiotoxin isolated from Formosan cobra venom. Naunyn Schmiedebergs Arch Pharmacol 259:360–374, 1968

  32. 32.

    Wang JP, Teng CM: Effect of anti-inflammatory drugs on the cardiotoxin induced hind-paw edema in rats. J Pharm Pharmacol 42:842–845, 1990

  33. 33.

    Condrea E, Barzilay A, Mager J: Role of cobra venom direct lytic factor and Ca2+ in promoting the activity of snake venom phospholipase A. Biochim Biophys Acta 210:65–73, 1970

  34. 34.

    Tu AT: Venoms, Chemistry and Molecular Biology, New York, John Wiley & Sons, 1977, p. 303

  35. 35.

    Paull KD, Shoemaker RH, Hodes L, Monks A, Scudeiro DA, Rubinstein L, Plowman J, Boyd R, Display, analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COM-PARE algorithm, J Natl Cancer Institute, 81:1088–1092, 1989

Download references

Author information

Correspondence to Robert A. Newman.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Newman, R.A., Vidal, J.C., Viskatis, L.J. et al. VRCTC-310 — A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity. Invest New Drugs 11, 151–159 (1993). https://doi.org/10.1007/BF00874149

Download citation

Key words

  • VRCTC-310
  • animal venom
  • phospholipase A2
  • cardiotoxin
  • crotoxin
  • Lewis lung carcinoma